	US 11,964,002 B2
	Means and methods for oral protein delivery
Nico Callewaert, Nevele (BE); Robin Vanluchene, Tielt (BE); Bram Laukens, Ghent (BE); Anna Depicker, Schelderode (BE); and Vikram Virdi, Ghent (BE)
Assigned to VIB VZW, Ghent (BE); and Universiteit Gent, Ghent (BE)
Appl. No. 16/489,265
Filed by VIB VZW, Ghent (BE); and UNIVERSITEIT GENT, Ghent (BE)
PCT Filed Feb. 28, 2018, PCT No. PCT/EP2018/054966 § 371(c)(1), (2) Date Aug. 27, 2019, PCT Pub. No. WO2018/158335, PCT Pub. Date Sep. 7, 2018.
Claims priority of application No. 17158471 (EP), filed on Feb. 28, 2017.
Prior Publication US 2020/0009229 A1, Jan. 9, 2020
Int. Cl. A61K 38/20 (2006.01); A23K 20/10 (2016.01); A23L 33/18 (2016.01); A61K 9/19 (2006.01); C07K 16/12 (2006.01); A61K 39/00 (2006.01)

CPC A61K 38/20 (2013.01) [A23K 20/10 (2016.05); A23L 33/18 (2016.08); A61K 9/19 (2013.01); C07K 16/1232 (2013.01); A23V 2002/00 (2013.01); A61K 2039/505 (2013.01); C07K 2319/30 (2013.01)]

17 Claims

1. A dried pharmaceutically acceptable formulation obtained by process comprising:

separating, from a culture medium in which a recombinant fungal host cell has been cultured, macromolecules smaller than 5 kDa so as to obtain a separated culture medium comprising macromolecules larger than 5 kDa; and

drying the separated culture medium so as to produce the dried pharmaceutically acceptable formulation,

wherein the separating of macromolecules smaller than 5 kDa is the only separation performed on the culture medium to remove macromolecules before drying;

wherein the separated culture medium comprises a polypeptide fused to an Fc domain secreted into the culture medium by the recombinant fungal host cell; and

wherein the polypeptide is exogenous to the recombinant fungal host cell.